symbol |
RXII |
会社名 | RXI Pharmaceuticals Corp (New) (RXIファ―マシュ―ティカルズ) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Major Pharmaceuticals
|
業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連(Health Care)
|
概要 |
事業概要 RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company''s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone a topical immunomodulator. Its clinical development programs include RXI-109 an sd-rxRNA for the treatment of dermal and ocular scarring and Samcyprone for the treatment of such disorders as warts alopecia areata non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas including dermatology ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence or down-regulate the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing enhancing or suppressing an immune response. RXIファ―マシュ―ティカルズは米国のバイオ医薬品会社。RNA干渉(RNAi)プラットフォ―ムに基づく治療の発見と開発、商品化に注力する。開発中のRNAi化合物には、「rxRNAori」と「sd-rxRNA」がある。また、臨床段階の主要な製品候補「RXI-109」は、皮膚瘢痕の予防や減少のために開発された「sd-rxRNA」である。
|
本社所在地 | 257 Simarano Drive Suite 101 Marlborough MA 01752 USA |
代表者氏名 | Robert J. Bitterman ロバートJ.ビッターマン |
代表者役職名 | Independence Chairman of the Board |
電話番号 | +1 508-767-3861 |
設立年月日 | 40787 |
市場名 | NASDAQ Small Cap |
ipoyear | ―年 |
従業員数 | - |
url | www.rxipharma.com |
nasdaq_url | https://www.nasdaq.com/symbol/rxii |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -8.52100 |
終値(lastsale) | 0.5687 |
時価総額(marketcap) | 2502280 |
時価総額 | 時価総額(百万ドル) 1.92558 |
売上高 | 売上高(百万ドル) 0.09600 |
企業価値(EV) | 企業価値(EV)(百万ドル) -3.38942 |
当期純利益 | 当期純利益(百万ドル) -8.61800 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 RXi Pharmaceuticals Corp revenues increased from $0K to $81K. Net loss decreased 48% to $4.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Acquired in-process research and develop decrease from $4.7M (expense) to $0K General and administrative expenses - Ba decrease of 22% to $1.6M (expense). |